Compare BFLY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | NVCR |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Switzerland |
| Employees | 220 | N/A |
| Industry | Medical Electronics | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | BFLY | NVCR |
|---|---|---|
| Price | $4.68 | $15.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.00 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 5.0M | 1.2M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $24.01 | $7.72 |
| Revenue Next Year | $19.93 | $6.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $1.32 | $9.82 |
| 52 Week High | $5.72 | $20.05 |
| Indicator | BFLY | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 69.77 |
| Support Level | $3.71 | $12.66 |
| Resistance Level | $5.00 | $15.09 |
| Average True Range (ATR) | 0.37 | 0.71 |
| MACD | -0.05 | 0.22 |
| Stochastic Oscillator | 40.30 | 89.93 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.